Dr. Cosgrove is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
210 SE 136th Ave
Vancouver, WA 98684Phone+1 360-944-9889Fax+1 360-944-9686
Summary
- Dr. Cosgrove specializes in general adult oncology with advanced subspecialty expertise in breast and gastrointestinal (GI) cancers. He is a strong advocate for bringing leading edge therapies to his patients through clinical trials. He serves on The US Oncology Research Network’s national GI Research Committee and as a principal investigator for many studies.
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2006 - 2009
- Johns Hopkins UniversityResidency, Internal Medicine, 2003 - 2006
- University College of Dublin National Univ SOMClass of 2000
Certifications & Licensure
- OR State Medical License 2015 - 2025
- WA State Medical License 2015 - 2025
- MD State Medical License 2006 - 2016
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
- QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer Start of enrollment: 2012 Jan 01
- Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy Start of enrollment: 2011 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 111 citationsGenomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic TargetsAndrew X. Zhu, Darrell R. Borger, Yuhree Kim, David Cosgrove, Aslam Ejaz
Annals of Surgical Oncology. 2014-06-03 - 1594 citationsPembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.Andrew X. Zhu, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara
The Lancet. Oncology. 2018-07-01 - 178 citationsCadmium Exposure and Liver Disease among US AdultsOmar Hyder, Michael Chung, David Cosgrove, Joseph M. Herman, Zhiping Li
Journal of Gastrointestinal Surgery. 2013-05-01
Other Languages
- German
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/david-cosgrove
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: